Community-based management versus traditional hospitalization in treatment of drug-resistant tuberculosis: a systematic review and meta-analysis
Tóm tắt
Multidrug drug resistant Tuberculosis (MDR-TB) and extensively drug resistant Tuberculosis (XDR-TB) have emerged as significant public health threats worldwide. This systematic review and meta-analysis aimed to investigate the effects of community-based treatment to traditional hospitalization in improving treatment success rates among MDR-TB and XDR-TB patients in the 27 MDR-TB High burden countries (HBC). We searched PubMed, Cochrane, Lancet, Web of Science, International Journal of Tuberculosis and Lung Disease, and Centre for Reviews and Dissemination (CRD) for studies on community-based treatment and traditional hospitalization and MDR-TB and XDR-TB from the 27 MDR-TB HBC. Data on treatment success and failure rates were extracted from retrospective and prospective cohort studies, and a case control study. Sensitivity analysis, subgroup analyses, and meta-regression analysis were used to explore bias and potential sources of heterogeneity. The final sample included 16 studies involving 3344 patients from nine countries; Bangladesh, China, Ethiopia, Kenya, India, South Africa, Philippines, Russia, and Uzbekistan. Based on a random-effects model, we observed a higher treatment success rate in community-based treatment (Point estimate = 0.68, 95 % CI: 0.59 to 0.76, p < 0.01) compared to traditional hospitalization (Point estimate = 0.57, 95 % CI: 0.44 to 0.69, p < 0.01). A lower treatment failure rate was observed in community-based treatment 7 % (Point estimate = 0.07, 95 % CI: 0.03 to 0.10; p < 0.01) compared to traditional hospitalization (Point estimate = 0.188, 95 % CI: 0.10 to 0.28; p < 0.01). In the subgroup analysis, studies without HIV co-infected patients, directly observed therapy short course-plus (DOTS-Plus) implemented throughout therapy, treatment duration > 18 months, and regimen with drugs >5 reported higher treatment success rate. In the meta-regression model, age of patients, adverse events, treatment duration, and lost to follow up explains some of the heterogeneity of treatment effects between studies. Community-based management improved treatment outcomes. A mix of interventions with DOTS-Plus throughout therapy and treatment duration > 18 months as well as strategies in place for lost to follow up and adverse events should be considered in MDR-TB and XDR-TB interventions, as they influenced positively, treatment success.
Tài liệu tham khảo
WHO. Global tuberculosis report 2015. 20th ed. Geneva: World Health Organization; 2015.
Geerligs WA, Van Altena R, De Lange WCM, Van Soolingen D, Van Der Werf TS. Multidrug-resistant tuberculosis: long term treatment outcome in the Netherlands. Int J Tuberc Lung Dis. 2000;4:758–64.
Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CR. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med. 1993;328:527–32.
Gupta R, Cegielski JP, Espinal MA, Henkens M, Kim JY, Lambregts-Van Weezenbeek CS, Lee JW, Raviglione MC, Suarez PG, Varaine F. Increasing transparency in partnerships for health—introducing the Green Light Committee. Trop Med Int Health. 2002;7(11):970–6.
Heller T, Lessells RJ, Wallrauch CG, Bärnighausen T, Cooke GS, Mhlongo L, Master I, Newell ML. Community-based treatment for multidrug-resistant tuberculosis in rural KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis. 2010;14(4):420–6.
Brust JC, Shah NS, Scott M, Chaiyachati K, Lygizos M, Van der Merwe TL, Bamber S, Radebe Z, Loveday M, Moll AP, et al. Integrated, home-based treatment for MDR-TB and HIV in rural South Africa: An alternate model of care. Int J Tuberc Lung Dis. 2012;16(8):998–1004.
Nathanson E, Nunn P, Uplekar M, Floyd K, Jaramillo E, Lönnroth K, Weil D, Raviglione MC. MDR-TB tuberculosis: critical steps for prevention and control. N Engl J Med. 2010;363:1050–8.
Baleta A. Forced isolation of tuberculosis patients in South Africa. Lancet Infect Dis. 2007;7(12):771. http://dx.doi.org/10.1016/S1473-3099(07)70281-5.
Padayatchi N, Friedland GH. Decentralised management of drug-resistant tuberculosis (MDR- and XDR-TB) in South Africa: an alternative model of care. Int J Tuberc Lung Dis. 2008;12(8):978–80.
Mitnick C, Bayona J, Palacios E. Community-based therapy for multi-drug resistant tuberculosis in Lima, Peru. N Engl J Med. 2003;348:119–28.
Oyieng’o DPP, Gardner A. Community-based treatment of multidrug-resistant tuberculosis: early experience and results from Western Kenya. Public Health Action. 2012;2:38–42.
Arshad A, Salam RA, Lassi ZS, Das JK, Naqvi I, Bhutta ZA. Community based interventions for the prevention and control of tuberculosis. Infect Dis Poverty. 2014;3(27):1–10.
Bekker L, Wood R. Community-based management of multidrug-resistant tuberculosis in South Africa. Int J Tuberc Lung Dis. 2010;14(4):379.
Vaghela JF, Kapoor SK, Kumar A, Dass RT, Khanna A, Bhatnagar AK. Home based care to multi-drug resistant tuberculosis patients: a pilot study. Indian J Tuberc. 2015;62(2):91–6.
Loveday M, Wallengren K, Brust J, Roberts J, Voce A, Margot B, Ngozo J, Master I, Cassell G, Padayatchi N. Community-based care vs. Centralised hospitalisation for MDRTB patients KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis. 2015;19(2):163–71.
Loveday M, Wallengren K, Voce A, Margot B, Reddy T, Master I, Brust J, Chaiyachati K, Padayatchi N. Comparing early treatment outcomes of MDR-TB in a decentralised setting with a centralised setting in KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis. 2012;16(2):209–15.
Mitnick CD, Shin SS, Seung KJ, Rich ML, Atwood SS, Furin JJ, Fitzmaurice GM, Alcantara VFA, Appleton SC, Bayona JN, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med. 2008;359(6):563–74.
Fitzpatrick C, Floyd K. A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis. PharmacoEconomics. 2012;30(1):63–80.
Weiss P, Chen W, Cook VJ, Johnston JC. Treatment outcomes from community-based drug resistant tuberculosis treatment programs: a systematic review and meta-analysis. BMC Infect Dis. 2014;14:333.
The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses [http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp]. Accessed 29 December 2015.
Vandenbroucke JP, Von EE, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M, Initiative S. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology. 2007;18(6):805–35.
Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328(7454):1490–4.
Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. edn: The Cochrane Collaboration; 2011. Available via HYPERLINK http://www.cochrane-handbook.org/. Accessed 14 Oct 2015.
OpenMetaAnalyst. Closing the Gap between Methodologists and End-Users: R as a Computational Back-End. In: Edited by Wallace BC, Issa J. Dahabreh, Thomas A. Trikalinos, Joseph Lau, Paul Trow, and Christopher H. Schmid, vol. 49, 5 edn: Journal of Statistical Software; 2012.
Baker WL, White CM, Cappelleri JC, Kluger J, Coleman CI, Group HOPaEHC. Understanding heterogeneity in meta-analysis: the role of meta-regression. Int J Clin Pract. 2009;63(10):426–34.
Ioannidis JP. Interpretation of tests of heterogeneity and bias in meta-analysis. J Eval Clin Pract. 2008;14(5):951–7.
Thompson SG, Higgins JPT. How should meta-regression analyses be undertaken and interpreted? Stat Med. 2002;21(11):1559–73.
Peters J, Sutton A, Jones D, Abrams K, Rushton L, Moreno S. Assessing publication bias in meta-analysis in the presence of between-study heterogeneity. J R Statist Soc. 2010;173:575–91. doi:10.1111/j.1467-985X.2009.00629.x.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1–34. doi:10.1016/j.jclinepi.2009.06.006.
Cox H, Hughes J, Daniels J, Azevedo V, McDermid C, Poolman M, Boulle A, Goemaere E, Van Cutsem G. Community-based treatment of drug-resistant tuberculosis in Khayelitsha, South Africa. Int J Tuberc Lung Dis. 2014;18(4):441–8.
Tupasi TE, Gupta R, Quelapio MI, Orillaza RB, Mira NR, Mangubat NV, Belen V, Arnisto N, Macalintal L, Arabit M et al. Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort study in the Philippines. PLoS Med. 2006;3(9):e352:1587–96.
Thomas A, Ramachandran R, Rehaman F, Jaggarajamma K, Santha T, Selvakumar N, Krishnan N, Mohan NS, Sundaram V, Wares F, et al. Management of multidrug resistance tuberculosis in the field: Tuberculosis Research Centre experience. Indian J Tuberc. 2007;54(3):117–24.
Joseph P, Desai VB, Mohan NS, Fredrick JS, Ramachandran R, Raman B, Wares F, Ramachandran R, Thomas A. Outcome of standardized treatment for patients with MDR-TB from Tamil Nadu, India. Indian J Med Res. 2011;133:529–34.
Singla R, Sarin R, Khalid UK, Mathuria K, Singla N, Jaiswal A, Puri MM, Visalakshi P, Behera D. Seven-year DOTS-Plus pilot experience in India: results, constraints and issues. Int J Tuberc Lung Dis. 2009;13(8):976–81.
Wei XLYJ, Zou GY, Zhang ZT, Walley J, Harwell J, Li HT, Sun Q, Li RZ, Wang LX, Zhang XL. Treatment interruption and directly observed treatment of multidrug-resistant tuberculosis patients in China. Int J Tuberc Lung Dis. 2015;19(4):13–9.
Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P, Rieder HL. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010;182(5):684–92.
Liu CH, Li L, Chen Z, Wang Q, Hu Y, Zhu B, Woo PC. Characteristics and treatment outcomes of patients with MDR and XDR tuberculosis in a TB referral hospital in Beijing: a 13-year experience. PLoS One. 2011;6(4):e19399:1-11.
Keshavjee S, Gelmanova IY, Farmer PE, Mishustin SP, Strelis AK, Andreev YG, Pasechnikov AD, Atwood S, Mukherjee JS, Rich ML, et al. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet. 2008;372(9647):1403–9.
Brust JC, Gandhi NR, Carrara H, Osburn G, Padayatchi N. High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa, 2000-2003. Int J Tuberc Lung Dis. 2010;14(4):413–9.
Shin SS, Pasechnikov AD, Gelmanova IY, Peremitin GG, Strelis AK, Mishustin S, Barnashov A, Karpeichik Y, Andreev YG, Golubchikova VT, et al. Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia. Int J Tuberc Lung Dis. 2007;11(12):1314–20.
Cox HSKS, Allamuratova S, Sizaire V, Tigay ZN, Rüsch-Gerdes S, Karimovich HA, Kebede Y, Mills C. Multidrug-resistant tuberculosis treatment outcomes in Karakalpakstan, Uzbekistan: treatment complexity and XDR-TB among treatment failures. PLoS One. 2007;2(11):e1126.
Hirpa S MG, Girma B, Melese M, Mekonen A, Suarez P, Ameni G. Determinants of multidrug-resistant tuberculosis in patients who underwent first-line treatment in Addis Ababa: A case control study. BMC Public Health. 2013;13(782):1–9.
Schroll JB, Moustgaard R, Gotzsche PC. Dealing with substantial heterogeneity in Cochrane reviews. Cross-sectional study. BMC Med Res Methodol. 2011;11(22):1–8.
Egger M, Juni P, Bartlett C, Holensteinn F, Sterne J. How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study. Health Technol Assess. 2003;7:1–68.
Isaakidis P, Casas EC, Das M, Tseretopoulou X, Ntzani EE, Ford N. Treatment outcomes for HIV and MDR-TB co-infected adults and children: systematic review and meta-analysis. Int J Tuberc Lung Dis. 2015;19(8):969–78.
Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS ONE. 2009;4(9):e6914.
WHO. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization; 2014.
Orenstein EW, Basu S, Shah SN, Andrews JR, Friedland GH, Moll AP, Gandhi NR, Galvani AP. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis. 2009;9:153–61.